ArticleHepatobiliary surgery and nutrition2025
Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma: survival outcomes and prognostic factors from a systematic review and meta-analysis.
Article in Hepatobiliary surgery and nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Article
- Survival Benefit of Combined Systemic and Locoregional Therapy in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Propensity Score-Matched Analysis.Liver cancer · 2026Article
- Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma in the Era of Systemic Therapies (2020-2025).Liver cancer · 2026Review
- Partial splenic embolization plus antitumor therapy for treating patients with hepatocellular carcinoma and splenomegaly: a case series study.Journal of gastrointestinal oncology · 2026Article
- Transarterial infusion chemotherapy combined with lenvatinib and tislelizumab versus intravenous chemotherapy for unresectable pancreatic ductal adenocarcinoma: a retrospective propensity score matching analysis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Advanced hepatocellular carcinoma (HCC) poses significant treatment challenges, with limited options and poor prognosis. Hepatic arterial infusion chemotherapy (HAIC) has emerged as a promising therapy, potentially offering superior outcomes compared to transarterial chemoembolization (TACE). This study aimed to systematically compare the survival outcomes and safety profiles of HAIC versus TACE in patients with advanced HCC, and to identify key prognostic factors influencing treatment efficacy to guide personalized therapeutic strategies. Methods: This meta-analysis included 14 studies assessing survival outcomes and safety profiles of HAIC versus TACE in advanced HCC. Overall survival (OS), progression-free survival (PFS), and adverse events were analyzed. Subgroup analyses evaluated the influence of prognostic factors such as tumor size, alpha-fetoprotein (AFP) levels, and vascular invasion. Results: HAIC significantly improved OS [hazard ratio (HR) =0.51] and PFS (HR =0.55) compared to TACE in advanced HCC. Subgroup analyses identified multiple prognostic factors favoring HAIC for better outcomes. For OS, HAIC showed significant benefits in subgroups including male gender (HR =0.57), AFP <400 ng/mL (HR =0.59), tumor number ≥3/5 (HR =0.75), hepatitis B virus (HBV)-positive patients (HR =0.50), vascular invasion (HR =0.50), extrahepatic metastasis (HR =0.55), and portal vein tumor thrombus (PVTT) presence (HR =0.34). For PFS, HAIC demonstrated superior outcomes in patients aged >60 years (HR =0.67), Eastern Cooperative Oncology Group (ECOG) ≥1 (HR =0.65), AFP ≥400 ng/mL (HR =0.48), tumor size ≥10 cm (HR =0.54), Child-Pugh A (HR =0.63), vascular invasion (HR =0.49), extrahepatic metastasis absence (HR =0.57), and Barcelona Clinic Liver Cancer (BCLC) Stage C (HR =0.64). Conclusions: HAIC offers significant survival benefits (OS and PFS) and a favorable safety profile compared to TACE in advanced HCC. These findings highlight HAIC as a valuable treatment option, particularly for patients with poor prognostic factors, and emphasize the need for personalized therapeutic strategies to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.